Base de dados : LILACS
Pesquisa : C04.557.465.625.650.240 [Categoria DeCS]
Referências encontradas : 57 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 6 ir para página                

  1 / 57 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1009006
Autor: De Oliveira Gomez, Diana C; Iglesias Forte, Rocío; Piñero Gutiérrez, Fátima K; Rosales Pereira, Katherine A; de Jesús Henriquez, Leidy C; Dávila Alcalá, Erik L; Zanella C, Fabian.
Título: Manifestación inusual de carcinoma neuroendocrino de células no pequeñas / Unusual presentation of a neuroendocrine lung non small cells carcinoma
Fonte: Med. interna (Caracas);33(4):244-250, 2017. ilus, tab.
Idioma: es.
Resumo: El dolor lumbar ocupa la primera causa de consulta por afección músculo-esquelética en el primer nivel de atención, siendo de suma importancia la enfermedad actual y los hallazgos al examen físico. Se presenta un caso clínico de un hombre de 60 años de edad con manifestaciones lumbares de alarma, al cual se le diagnosticó un carcinoma neuroendocrino de células no pequeñas de pulmón en etapa avanzada. Se discuten las características generales e histogénesis del tumor, así como las estrategias de tratamiento, teniendo en cuenta que esta enfermedad es infrecuente y representa un difícil diagnóstico(AU)

Lumbar pain is the first cause of consultation for musculoskeletal affections in the primary level of attention. The history and findings on physical examination are very important. We present a case of a sixty years-old man with lumbar alarming manifestations. He was diagnosed with a neuroendocrine carcinoma of non-small lung cells at an advanced stage. The assessment and histogenesis of the tumor are discussed, as well as the treatment strategies(AU)
Descritores: Carcinoma Neuroendócrino/patologia
Carcinoma Pulmonar de Células não Pequenas/patologia
Carcinoma Pulmonar de Células não Pequenas/diagnóstico por imagem
-Ultrassonografia Doppler
Medicina Interna
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: VE1.1 - Biblioteca Humberto Garcia Arocha


  2 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1000444
Autor: Panchana Egüez, Guido; Macías Fernández, Pamela; Zambrano, Diego A; Lara Perlaza, Mauricio; Panchana Coello, Guido.
Título: Distribución Topográfica y Manejo de Tumores Neuroendocrinos del Tubo Digestivo / Topographic Distribution and Management of Neuroendocrine Tumors of the Digestive Tube
Fonte: Oncol. (Guayaquil) = Oncol. (Guayaquil);29(1):27-35, 30 de abril 2019.
Idioma: es.
Resumo: Introducción: Los tumores neuroendocrinos (TNE) son un grupo de neoplasias que se originan a partir de células enterocromafínicas, especialmente ubicadas en el tubo digestivo. El objetivo del presente estudio es escribir la distribución topográfica, el manejo multidisciplinario y diagnóstico patológico según la OMS de los tumores neuroendocrinos del tubo digestivo. Métodos: El presente es un estudio descriptivo, retrospectivo de los casos con diagnóstico anatomopatológico confirmado de tumor neuroendocrino localizados en el tubo digestivo entre enero del 2011 a diciembre del 2018 en el Instituto Oncológico Nacional del Ecuador- SOLCA de Guayaquil. Se describe topografía y tipo de tratamiento establecido con frecuencias y porcentajes. Resultados: Ingresaron al estudio 21 casos. La localización más frecuente fue el apéndice cecal n = 8 (38 %), en estómago n=4 (19 %), intestino delgado n=3 (14 %). El diagnóstico patológico en estadio G1 (65 %); G2 (24%) y G3 (12%). La primera línea de tratamiento fue la cirugía con intención curativa n=19 (90.5 %) y tratamiento endoscópico n=2 (9.5 %). Los pacientes sometidos a cirugía, n=16/19; (84 %) obtuvieron niveles de resección 0 (R0) y permanecieron en observación clínica, los demás sujetos en el estudio recibieron tratamiento adyuvante con somatostatina sola n=1 (4.8 %) o combinación de somatostatina y radioterapia n=2 (9.5 %). Conclusión: El diagnóstico de tumor neuroendocrino de tubo digestivo es una etiología oncológica poco frecuente. El tratamiento quirúrgico en esta serie de casos está enfocada en una acción curativa de tipo quirúrgico.

Introduction: Neuroendocrine tumors (NETs) are a group of neoplasms that originate from enterochromaffin cells, especially located in the digestive tract. The objective of the present study is to write the topographic distribution, the multidisciplinary management and pathological diagnosis according to the WHO of the neuroendocrine tumors of the digestive tract. Methods: This is a descriptive, retrospective study of the cases with a confirmed anatomopathological diagnosis of neuroendocrine tumor located in the digestive tract between January 2011 to December 2018 at the National Oncology Institute of Ecuador- SOLCA of Guayaquil. The topography and type of treatment established with frequencies and percentages are described. Results: 21 cases were entered into the study. The most frequent location was the cecal appendix n = 8 (38%), stomach n = 4 (19%), small intestine n = 3 (14%). The pathological diagnosis in stage G1 (65%); G2 (24%) and G3 (12%). The first line of treatment was surgery with curative intent n = 19 (90.5%) and endoscopic treatment n = 2 (9.5%). Patients undergoing surgery, n = 16/19; (84%) obtained resection levels 0 (R0) and remained under clinical observation, the other subjects in the study received adjuvant treatment with somatostatin alone n = 1 (4.8%) or combination of somatostatin and radiotherapy n = 2 (9.5%). Conclusion: The diagnosis of neuroendocrine tumor of the digestive tract is a rare oncological etiology. The surgical treatment in this series of cases is focused on a surgical action of a surgical type.
Descritores: Tumor Carcinoide
Trato Gastrointestinal
Trato Gastrointestinal Inferior
-Apêndice
Carcinoma Neuroendócrino
Trato Gastrointestinal Superior
Limites: Seres Humanos
Tipo de Publ: Estudo Observacional
Responsável: EC104.1 - Biblioteca


  3 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Meneses, Antonio Carlos Oliveira
Texto completo
Id: biblio-986588
Autor: Guimarães, Lucinda Calheiros; Garcia, Priscila Leandro; Castro Filho, João Badaró; Meneses, Antonio Carlos Oliveira.
Título: Primary endometrial large cell neuroendocrine carcinoma with melanocytic differentiation
Fonte: Autops. Case Rep;8(4):e2018041, Oct.-Dec. 2018. ilus.
Idioma: en.
Resumo: High-grade endometrial carcinomas are aggressive neoplasms of difficult histological classification. Neuroendocrine differentiation in endometrial carcinomas is rare. This is the report of an endometrial large cell neuroendocrine carcinoma with foci of melanocytic differentiation in a 75-year-old woman with abnormal post-menopausal uterine bleeding for 2 years. Two initial biopsies were inconclusive. Histopathological examination of the uterus revealed large cell neuroendocrine carcinoma associated with endometrioid carcinoma and foci of melanocytic differentiation, pT3a (FIGO IIIA). There were metastases in the rectum serosa and lungs. After 8 months of diagnosis and surgical treatment, the patient is on chemotherapy and radiotherapy. We highlight the morphological characteristics and criteria that allow the definitive anatomopathological diagnosis, including immunohistochemical markers used to identify the cell types present in this unprecedented association.
Descritores: Neoplasias do Endométrio/diagnóstico
Carcinoma Neuroendócrino/diagnóstico
-Imuno-Histoquímica
Neoplasias do Endométrio/cirurgia
Carcinoma Neuroendócrino/cirurgia
Carcinoma de Células Grandes
Melanócitos
Limites: Seres Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Conferência Clínica
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  4 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-910537
Autor: Mehrara, E; Forssell-Aronsson, E.
Título: Estimation of tumour volume at therapy initiation by back-extrapolating the post-therapy regression curve of tumour volume
Fonte: Appl. cancer res;38:1-5, jan. 30, 2018. ilus.
Idioma: en.
Resumo: Background: Tumour volume at therapy initiation, Vi, is rarely available in cancer patients, and the last pre-treatment tumour volume available is from previous diagnostic imaging (Vd). Therapeutic efficacy is thus evaluated by comparing tumour volume after treatment with Vd, instead of Vi, which results in underestimation of treatment efficacy. Vi, together with Vd, can also be used for estimation of the natural growth rate of tumour valuable for, e.g., screening programs, prognostication and individualised treatment planning such as chemotherapy scheduling. The aim of this work was to study the feasibility of estimating Vi by back-extrapolating the post-therapy regression of tumour volume, based on data from animal model. Methods: Nude mice bearing human neuroendocrine GOT1 tumour cell line were treated with 177Lu-DOTA-TATE. Tumour volumes were measured regularly after therapy and Vi was estimated by back-extrapolation of (a) linear and (b) exponential regression lines of the two earliest post-therapy tumour volumes and (c) the long-term exponential regression of tumour volume. The estimated Vi values (Vest) were compared with the measured volume of tumour at therapy initiation. Results: The linear regression of the two earliest post-therapy tumour volumes gave the best estimate for Vi (Vest = 0.91 Vi, p < 0.00001), compared with the exponential regression models either on short-term (Vest = 2.30 Vi, p < 0.01), or long-term (Vest = 0.93 Vi, non-significant) follow up of tumour volume after therapy. Conclusion: Back-extrapolation of the early linear regression of tumour volume after therapy gave the best estimate for tumour volume at time of therapy initiation. This estimate can be used as baseline for treatment efficacy evaluation or for estimation of the natural growth rate of tumour (together with the measured tumour volume at pre-treatment diagnostic imaging)
Descritores: Carcinoma Neuroendócrino
Linhagem Celular Tumoral
Diagnóstico por Imagem
Neoplasias
Limites: Animais
Ratos
Responsável: BR30.1 - Biblioteca


  5 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-907765
Autor: Román-González, Alejandro; Sierra-Zuluaga, Juliana; Gutiérrez-Restrepo, Johnayro; Builes-Barrera, Carlos A; Jiménez-Vásquez, Camilo.
Título: Feocromocitoma-paraganglioma: revisión de tema / Pheochromocytoma-paraganglioma: a review
Fonte: Med. lab;21(3-4):111-130, 2015. ilus, tab.
Idioma: es.
Resumo: Resumen: el feocromocitoma es una enfermedad poco frecuente, correspondiente a un tumor derivadode las células cromafines, originado en la médula de la glándula suprarrenal. Cuando este tumor se origina en los paraganglios el término correcto es paraganglioma. Las manifestaciones clínicas son variables y secundarias a la masa tumoral o a la producción exagerada de catecolaminas. Los síntomas originados por el crecimiento de la masa tumoral incluyen dolor abdominal, malestar epigástrico, obstrucción de estructuras cercanas como la vía biliar y los uréteres, y, cuando está localizado en otros sitios como el mediastino, disnea. Los síntomas secundarios a la hiperproducción de catecolaminas son diaforesis, palpitaciones, cefalea, crisis hipertensivas, hipertensión sostenida, constipación, náuseas, vómito y, en la forma más exagerada, crisis catecolaminérgicas. El diagnóstico se realiza mediante la medición de metanefrinas libres en orina de 24 horas o en plasma, y como alternativa se puede realizar medición de catecolaminas en orina de 24 horas. La medición de ácido vanilmandélico es poco sensible, lo mismo que la medición de catecolaminas en plasma, la cual no es recomendada. El tratamiento de esta enfermedad es quirúrgico. En aquellos pacientes con feocromocitomamaligno o paraganglioma se puede realizar una estrategia de observación activa y en quienes tengan progresión de la enfermedad el uso de quimioterapia o, según el grado de compromiso, el uso de metayodobencilguanidina marcada con yodo-131 es la terapia de elección. El uso de terapia molecular diana utilizando inhibidores de tirosina quinasa es un área de investigación activa.

Abstract: Pheochromocytoma is a rare disease, corresponding to a tumor originated in the chromaphincells, and located in the adrenal medulla. When the tumor is located in the paraganglia the appropriate term is paraganglioma. Clinical manifestations are variable and secondary to the tumoral local extension or to the overproduction of catecholamines. Symptoms secondary to local growth of the tumor includes abdominal pain, epigastric discomfort, obstruction of nearby structures such as biliary tree and ureters, and when is located in other regions such as the mediastinum, dyspnea. Symptoms secondary to overproduction of catecholamines are diaphoresis, headache, hypertensive emergencies, sustained hypertension, constipation, nausea, vomiting and, in the most extreme form, catecholaminergic crisis. Diagnosis is based on the measurement of free plasmatic or urinary metanephrines.As an alternative can be used 24 hours urinary catecholamines. The detection of vanillylmandelic acid and plasma catecholamines has poor sensibility and is no longer recommended. The treatment of this entity is surgical resection. In those patients with malignant pheochromocytoma or paraganglioma an observation and watch strategy can be used. If disease progression is detected, the use of chemotherapy or iodine-131-labeled meta-iodobenzylguanidine, according to the severity of compromise, is the next step. The use of targeted molecular therapies using tyrosine kinase inhibitoris an area under active research.
Descritores: Carcinoma Neuroendócrino
Catecolaminas
Metanefrina
Paraganglioma
Feocromocitoma
Limites: Seres Humanos
Tipo de Publ: Revisão
Revisão
Responsável: CO373.9 - EDIMECO - Editora Médica Colombiana S.A.


  6 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-905609
Autor: Póvoa, Sara; Azevedo, Daniela; Marques, Cristiana; Barroca, Helena; Costa, Andreia.
Título: Unknown primary large-cell neuroendocrine tumor
Fonte: Autops. Case Rep;8(2):e2018025, Apr.-May 2018. ilus.
Idioma: en.
Resumo: Large-cell neuroendocrine tumors (NETs) are poorly differentiated malignancies of rare incidence and aggressive nature. NETs mostly arise in the lung followed by the gastrointestinal tract, although they are potentially ubiquitous throughout the body. Primary unknown NET has a worse prognosis and shorter survival comparing with other NETs, with limited available data in the literature concerning this subgroup. The authors report the case of large-cell NET with supraclavicular lymph node presentation. Total excisional biopsy revealed an enlarged adenopathy 18 × 15 × 10 mm, which was extensively infiltrated by a solid malignant neoplasm composed of large cells with granular chromatin, nuclear pseudo-inclusions, high mitotic index, and focal necrosis, with a Ki 67 index 25-30% and positive immunohistochemical study for the expression of cytokeratin 8/18, chromogranin, synaptophysin, and thyroid transcriptional factor-1 (TTF-1). There was no evidence of primary location apart from two infracentimetric lung lesions that could not be accessed for biopsy and were negative at both somatostatin receptor scintigraphy and positron emission tomography. The NET relapsed with three mediastinal masses, so the patient was started on chemotherapy with carboplatin and etoposide with initial total response. Early progression showed no response to further chemotherapy regimens (temozolomide, oral etoposide); therefore, the patient was treated with local radiotherapy. This patient has an atypical long survival (54 months) compared to the literature data. In fact, there are few long-term survivors of large-cell NET and they are all related to complete surgical resection.
Descritores: Carcinoma Neuroendócrino
Neoplasias Primárias Desconhecidas
-Carboplatina/uso terapêutico
Carcinoma de Células Grandes
Etoposídeo/uso terapêutico
Tumores Neuroendócrinos
Limites: Seres Humanos
Feminino
Idoso
Tipo de Publ: Relatos de Casos
Conferência Clínica
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  7 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-905127
Autor: Azevedo, Daniela; Rios, Elisabete; Vendeira, Lurdes; Sarmento, Cristina.
Título: Small cell neuroendocrine carcinoma of the nasopharynx: a rare case report
Fonte: Autops. Case Rep;7(1):31-35, Jan.-Mar. 2017. ilus, tab.
Idioma: en.
Resumo: Small cell neuroendocrine carcinoma rarely appears primarily in the head and neck and exhibits aggressive behavior with a poor prognosis. The pathologist has a significant role in the diagnosis, and a consensual treatment still does not exist. The authors report the case of a middle-aged male patient who presented repeated episodes of massive epistaxis. The diagnostic work-up disclosed the diagnosis of small cell neuroendocrine carcinoma of the nasopharynx. The patient was treated with chemotherapy followed by radiotherapy. Imaging examinations performed after the end of treatment showed apparent complete remission of the disease. The patient was kept under active surveillance with no signs of local relapse or distant metastasis after 4 years of follow-up.
Descritores: Carcinoma Neuroendócrino/terapia
Carcinoma de Células Pequenas/terapia
Nasofaringe/patologia
-Carcinoma Neuroendócrino/tratamento farmacológico
Carcinoma Neuroendócrino/radioterapia
Epistaxe/etiologia
Indução de Remissão
Limites: Seres Humanos
Masculino
Meia-Idade
Tipo de Publ: Relatos de Casos
Responsável: BR26.7 - Serviço de Biblioteca e Documentação Científica


  8 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-904912
Autor: Arango, Marcela; Tobón, Adriana; Correa, Andrea; Robayo, Juan.
Título: Pérdida de la agudeza visual como primera manifestación del cáncer de páncreas: Reporte de caso / Visual acuity loss as first manifestation of pancreatic cancer: Case report
Fonte: Rev. Soc. Colomb. Oftalmol;50(1):39-44, 2017. ilus., tab..
Idioma: es.
Resumo: Las metástasis oculares constituyen el tumor maligno intraocular más frecuente en la población adulta. Estas tienen en su mayoría un compromiso coroideo. Se describe el caso de una paciente que presentó disminución de la agudeza visual rápidamente progresiva en el ojo derecho. Sin antecedentes personales relevantes, durante la evaluación oftalmológica se observa una lesión coroidea, la cual clínica y radiológicamente sugería una metástasis coroidea como primera impresión diagnóstica. Posterior a la realización de estudios de extensión se confirmó histopatológicamente un tumor pancreático como origen de la metástasis. Las metástasis oculares ocasionadas por el páncreas son extremadamente raras, lo cual se confirma en la revisión de la literatura realizada.

The ocular metastases are the most common intraocular malignant tumor in the adult population. These have mostly a choroid commitment. This case report describes a female patient who presented with a rapidly progressive decrease in visual acuity in the right eye, no other symptoms were referred and her medical history was no relevant. A choroidal lesion was found, which clinically and radiologically suggested a choroid metastasis as the diagnosis. With extension studies was confi rmed histopathologically a pancreatic tumor as the primary tumor. The ocular metastases that are originated for the pancreas are extremely rare; this is confirmed by the review of the literature.
Descritores: Neoplasias Oculares
-Carcinoma Neuroendócrino
Oftalmopatias
Neoplasias Pancreáticas
Limites: Seres Humanos
Tipo de Publ: Relatos de Casos
Responsável: CO119


  9 / 57 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: lil-786475
Autor: Pérez P., Romero; Navarro Antón, J. A; Amat, Cecilia; Merenciano Cortina, FJ; Lapuerta Torres, F. E; Ferrero, Doria R; Vaquero, M.
Título: Carcinoma neuroendocrino de vejiga en mujer con infección por VIH: presentación del primer caso mundial / Neuroendocrine carcinome of the bladder in a female with HIV infection: presentation of the first case worldwide
Fonte: Rev. chil. urol;80(1):31-37, 2015. tab, ilus.
Idioma: es.
Resumo: El carcinoma neuroendocrino primario de vejiga es una neoplasia infrecuente que representa el 0,5por ciento de todos los tumores vesicales. La asociación de carcinoma neuroendocrino de vejiga en un paciente con infección por VIH nunca hasta hoy había sido descrita. Presentamos el primer caso clínico español y mundial de esta desconocida y nunca descrita asociación. MATERIAL Y MÉTODOS: Se presenta el caso clínico de una paciente de 46 años con infección por VIH que desarrolló un carcinoma neuroendocrino de vejiga urinaria de evolución fatal. Se describe su clínica de presentación, métodos de diagnóstico utilizados y su tratamiento. La paciente debutó con retención urinaria aguda que rápidamente progresó a la instauración de una uropatía obstructiva alta con deterioro de la función renal. El diagnóstico se efectuó mediante TAC, resección transuretral y estudio histopatológico donde la clave del diagnóstico fue el estudio inmunohistoquímico intensamente positivo para la cromogranina A. El tratamiento adyuvante con quimioterapia le ocasionó una aplasia medular severa, falleciendo por fallo multiórganico a los 26 días de su diagnóstico. A propósito de este caso, se revisa la literatura inglesa en PubMed sobre carcinoma neuroendocrino de vejiga y sobre tumores vesicales en pacientes con infección VIH, no existiendo ningún caso publicado de carcinoma neuroendocrino de vejiga en un paciente con infección por VIH. CONCLUSIONES: El carcinoma neuroendocrino de vejiga es un tumor infrecuente y muy agresivo. Es un tumor que suele presentarse clínicamente en estadios avanzados o metastásicos donde ninguna terapia es eficaz. El tratamiento incluye resección trans-uretral (RTU), cistectomía parcial, cistectomía radical y quimioterapia. El estudio inmunohistoquímico (IHQ) y la tinción con cromogranina A dan la clave para su diagnóstico. Su presentación en pacientes VIH implica muy mal pronóstico. Éste caso es el primer caso mundial publicado de carcinoma neuroendocrino...

The primary neuroendocrine carcinome of the bladder is an infrequent neoplasm which represents 0.5 percent of all vesical tumors. The association of neuroendocrine carcinome of the bladder in a patient with HIV infection has never been described before today. We present the first clinical case in the Spanish-speaking world and worldwide, of this unknown and never written about association. MATERIAL AND METHODS: The clinical case of a 46-yearoldpatient with HIV infection who developed a neuroendocrine carcinoma of the urinary bladder with a fatal evolution, its clinical presentation, the diagnosis methods used and its treatment, are described. The patient started with a severe urinary retention which rapidly progressed to the establishment of a high obstructive uropathy with deterioration in the renal function. The diagnosis was done using TAC, transurethral resection and histopathological study where the key to diagnosis was the intensely positive immunohistochemical study for the chromogranin A. The adjuvant treatment with chemotherapy led to a severe medular aplasia, with the patient dying due to a multi-organ failure, 26 days after her diagnosis. As a result of this case, English literature on the matter in PubMed about neuroendocrine carcinome of the bladder and about vesical tumors in patients with HIV infection was revised, with no published case existing about neuroendocrine carcinome in a patient with HIV. CONCLUSIONS: The neuroendocrine carcinome of the bladder is an infrequent and very aggressive tumor. It is a tumor that tends to be clinically present in advanced or metastasic states, where no therapy is efficient. The treatment includes transurethral resection (TUR), partial cystectomy, radical cystectomy and chemotherapy. The immunohistochemical study (IHC), and the stain with chromogranin A are key for its diagnosis. Its presentation in HIV patients implies a very bad prognosis. This case is the first published case worldwide of neuroendocrine...
Descritores: Carcinoma Neuroendócrino/complicações
Infecções por HIV/complicações
Neoplasias da Bexiga Urinária/complicações
-Evolução Fatal
Limites: Seres Humanos
Feminino
Meia-Idade
Tipo de Publ: Relatos de Casos
Revisão
Responsável: CL10.1 - Biblioteca Biomédica


  10 / 57 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Id: lil-767920
Autor: Siqueira, Pedro Freire de; Mathez, Andréia Latanza Gomes; Pedretti, Denize Borges; Abucham, Julio.
Título: Pituitary metastasis of lung neuroendocrine carcinoma: case report and literature review
Fonte: Arch. endocrinol. metab. (Online);59(6):548-553, Dec. 2015. tab, graf.
Idioma: en.
Resumo: SUMMARY Metastasis to the pituitary gland is an unusual situation in clinical practice, but the frequency thereof is increasing due to the increased survival of cancer patients, and greater availability of imaging. In most cases, they are found between the sixth and seventh decades of life, as determined in image examination of patients with known malignant neoplasm, but, generally, asymptomatic with respect to pituitary involvement. The most common primary sites are breast in women and lung in men. We present the case of a 64-year-old patient with clinical visual changes, polyuria, polydipsia, and decreased level of consciousness whose tests showed pan-hypopituitarism, hypernatremia and low urine specific gravity, and extensive mass in sellar region. Diabetes insipidus was confirmed and treated, corticotrophic and thyroid deficits were corrected and then the patient underwent resection by transsphenoidal surgery. The histopathological and immunohistochemistry analysis revealed pituitary metastasis of lung neuroendocrine tumor. Subsequently, a chest CT scan showed pulmonary mass consistent with primary neoplasm. Despite the water and electrolyte correction and intravenous glucocorticoid replacement, the patient continued to show decreased level of consciousness due to compression of the brain stem by the pituitary mass, evolving to death. The purpose is to call attention to the differential diagnosis of invasive lesions of the sellar region, mainly in individuals over 50 years and/or when associated with diabetes insipidus, as it may be a case of metastasis, although there is no known primary neoplasm. Arch Endocrinol Metab. 2015;59(6):548-53.
Descritores: Carcinoma Neuroendócrino/secundário
Neoplasias Pulmonares/patologia
Neoplasias Hipofisárias/secundário
-Biópsia
Estado de Consciência
Proteínas de Ligação a DNA/isolamento & purificação
Evolução Fatal
Imuno-Histoquímica
Limites: Feminino
Seres Humanos
Meia-Idade
Tipo de Publ: Relatos de Casos
Revisão
Responsável: BR1.1 - BIREME



página 1 de 6 ir para página                
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde